Stock search

Ticker or company name

Veeva Systems

VEEV · NYSE · Health Care

$299,28Down −2,25 (−0,75%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$50,7 bn
Div. yield
—
Year to date
+35,1%
52 weeks: $148,05$325,99

Ratio score

89/100
Ratio would consider buying

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

8 ✓ · 0 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM47,355,525,1
Forward P/E33,6—16,2
PEG2,1—2,2
P/S13,913,42,2
EV/EBITDA43,252,417,3
P/FCF29,3—19,5
P/B6,57,03,4

Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 35 analysts

Buy
26
Hold
8
Sell
1

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q2 20272,272,35Up +3,7%
Q1 20272,172,24Up +3,0%
Q4 20261,972,06Up +4,5%
Q3 20261,992,04Up +2,6%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue928 m883 m836 m811 m789 m759 m721 m699 m676 m650 m631 m617 m
EPS1,661,571,481,401,191,371,171,131,040,980,900,83
Margin29,5%29,6%29,2%29,1%25,4%30,1%27,1%26,6%25,3%24,9%23,4%21,9%
FCF239 m1,13 bn107 m193 m238 m877 m69,5 m164 m92,9 m764 m57,8 m82,6 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $16,8 m.

NameAmountSharesPrice
faddis jonathan14 Oct 2026 · sale$211 120708$298,19
faddis jonathan14 Oct 2026 · sale$291 810975$299,29
faddis jonathan14 Oct 2026 · sale$1,05 m3 515$300,14
rizzo daniel j2 Oct 2026 · sale$88 662321$276,21
rizzo daniel j2 Oct 2026 · sale$1,25 m4 520$276,53
schwenger thomas d.14 Sep 2026 · sale$265 2001 000$265,20
hung priscilla9 Sep 2026 · sale$195 780750$261,04
schwenger thomas d.27 Aug 2026 · sale$2,81 m10 000$281,33
schwenger thomas d.13 Aug 2026 · sale$456 6201 819$251,03
schwenger thomas d.13 Aug 2026 · sale$8,31 m33 181$250,44
schwenger thomas d.13 Aug 2026 · sale$241 9101 000$241,91
schwenger thomas d.16 Jul 2026 · sale$1,00 m5 000$200,00
hung priscilla30 Apr 2026 · sale$116 730750$155,64
hung priscilla10 Apr 2026 · sale$115 125750$153,50
schwenger thomas d.5 Mar 2026 · sale$200 0001 000$200,00

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Health Care
Exchange
NYSE
Country
US
IPO date
16 Oct 2013

Company description, revenue by segment and region, and the CEO will come later.

Next report
3 Dec 2026, after close

An AI summary of the earnings call will come later.

Peers

CompanyPrice
HUMHumana$461,2561would watch44,0+22,0%0,8%
IDXXIdexx Laboratories$700,6583would consider47,2+11,9%25,4%
BDXBecton Dickinson$216,4738would not consider51,8−2,6%4,5%
EWEdwards Lifesciences$107,1156would watch60,3+13,4%15,2%
BSXBoston Scientific$43,6983would consider18,4+8,9%16,6%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.